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Sir,
We have read with great interest the article by Hurst et al (2007).
In their study, they make prospective predictions—that is, without
knowing the definitive diagnosis—of underlying colorectal
neoplasia (their Figure 1) based on serum MMP-9 (sMMP-9)
concentration. The criterion they use to prospectively classify
patients is the ratio of measured to predicted sMMP-9 concentra-
tion, where a ratio greater than one indicates neoplasia and less
than or equal to one indicates non-neoplasia. The model was fitted
using only normal, disease-free individuals and then, as far as we
are able to ascertain, applied to all (diseased and disease-free)
individuals.
We recognise that one of the strengths of this study is that blood
was collected before diagnosis of disease, thereby, removing a
potential source of bias. Nevertheless, it is not clear to us why
prospective prediction was carried out and reported, especially
when the authors subsequently carry out a regression analysis that
yields much better sensitivity and specificity. We also do not
understand why an observed to predicted ratio of one ought to
provide an optimal cutoff to prospectively distinguish between
non-neoplasia and neoplasia. Finally, the R
2 value of 0.027 quoted
by the authors is extremely small, and unless it is a misprint,
indicates that the data do not support the assertion of a
relationship between sMMP-9 concentration and patient age.
Indeed, it is straightforward to show that in the absence of any
relationship, the ‘predicted’ value is simply the mean sMMP-9
concentration of the normal, disease-free observations and is,
therefore, the cutoff point for prospectively predicting non-
neoplasia or neoplasia.
Lack of space may have precluded its inclusion, but a plot of
sMMP-9 concentration against age would have assisted readers in
judging whether fitting a model relating concentration and age was
justified. Moreover, whether or not concentration depends on
other covariates, it would be useful to display the measured
concentrations of sMMP-9—as boxplots, for example— for all
subgroups in Figure 1 of their paper.
In a burgeoning field, such as biomarker discovery and
validation, where considerable effort is required to generate
reliable data—as Hurst et al have demonstrated here—and where
well-known and novel statistical methods are employed for data
analysis, authors should be encouraged to publish raw data in
web-based appendices to allow others to independently reproduce
their data analyses (Altman and Cates, 2001; Hutchon, 2001). We
note that policy of British Journal of Cancer requires authors to
make available to readers materials that are not readily available
from commercial suppliers, and this requirement could be
extended to data, which could be made available as supplementary
online material.
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